Antibody Discovery
Built on the unique architecture of shark IgNAR, we prepare a new class of nanobodies — small, highly stable and strongly tissue-penetrating.
The VNAR domain of shark IgNAR is the smallest functional antigen-binding fragment known — tolerant of heat, pH extremes and protease degradation, with very low immunogenicity — suiting detection in harsh environments and penetrating targeted delivery.
Phage display and single B cell platforms run in parallel for VNAR screening, with stability and low-immunogenicity optimisation planned before the project starts.
A one-stop, fully customised workflow runs from antigen preparation, shark immunization, library construction and specificity screening through high-yield expression and purification, and on to affinity maturation and humanization.
Enquire now →
Focused on VNAR's small size, exceptional stability and low immunogenicity — suited to extreme conditions and demanding targets.
Built on a proven framework with targeted process upgrades — no need to build from scratch, so projects land efficiently.
Two platforms tuned for VNAR screening safeguard clone activity and specificity while reducing screening risk.
A customised plan is set upfront, strengthening stability and low-immunogenicity optimisation and cutting trial-and-error cost.
Eight stages. The antigen and stable cell line can be supplied by you, in which case step 02 is skipped; each stage's outputs and acceptance criteria are in the specifications below.
Antigen format and immunization plan defined from the target's structure; antigen supplied by you or prepared by SanjingBio
Recombinant antigen purity ≥85%; a stable cell line is built in parallel for membrane-protein targets
Four immunizations with titre testing over 7 weeks, serum titre ≥1:100,000
Peripheral-blood immune cells are isolated to build a high-quality VNAR library
VNAR library construction and screening — library ≥1×10⁹ CFU, enrichment ≥20-fold
Candidate sequences are recombinantly expressed and purified following ELISA screening of ≥20 positive clones
Affinity and function verified by ELISA and flow cytometry, EC50 <10 nM
Purified antibodies, sequencing reports, immunization records and all raw data delivered
Screening and delivery stages total roughly 20–22 weeks. Commissioned antigen preparation adds 1–6 weeks; stable cell line development adds 4–8 weeks.
Years of nanobody know-how back two platforms running in parallel for VNAR screening, safeguarding clone activity and specificity. Stability and low-immunogenicity optimisation is planned before kickoff, balancing speed with antibody quality.
Deliverables, acceptance criteria and timelines by experimental stage. The staging differs from the process above: the process shows how a project runs, while this table is the acceptance basis written into the contract.
| Stage | Scope | Deliverables | Standards | Timeline |
|---|---|---|---|---|
| Antigen preparation | Design, synthesis and expression | Remaining antigen | Purity ≥85%, concentration ≥1 mg/mL | 1-6 weeks |
| Stable cell line development | Development of a cell line stably expressing the target protein | Stable cell line with expression report | Positive expression report for the cell line | 4-8 weeks |
| Shark immunization | Four immunizations with titre testing | Immunization records | Serum titre ≥1:100,000 (ELISA) | 7 weeks |
| Library construction & screening | VNAR library construction and screening | Enriched library | Library size ≥1×10⁹ CFU, insertion rate ≥95%, positive-clone enrichment ≥20-fold | 7 weeks |
| Monoclonal identification | ELISA screening | ELISA screening data for ≥20 positive clones | Positive rate ≥30% | 1 week |
| Sequencing & analysis | Sanger sequencing | ≥20 sequencing reports (FASTA) with sequence analysis | All sequences delivered with CDR and germline analysis | 1 week |
| Recombinant expression | Expression and purification | Purified antibody (1 mg per clone) with SDS-PAGE report | Purity ≥95%, concentration ≥1 mg/mL | 2-4 weeks |
| Functional validation | Affinity verified by ELISA and FCM | Detailed functional validation data report | EC50 <10 nM | 2 weeks |
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
